Results 291 to 300 of about 73,607 (303)

Inhibition of JAK2/STAT3 signalling induces colorectal cancer cell apoptosis via mitochondrial pathway

Journal of Cellular and Molecular Medicine, 2012
Wan Du, Ying-Chao Wang, Yan-Jie Zhang
exaly  

The JAK2 V617F mutation in de novo acute myelogenous leukemias

Oncogene, 2005
Y G Kim, Woo Sung Min, Nam Jin Yoo
exaly  

Expression of p‐JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia

International Journal of Cancer, 2011
Takayuki Ikezoe, Chie Nishioka, H Phillip Koeffler   +2 more
exaly  

Jak2 inhibitors: Rationale and role as therapeutic agents in hematologic malignancies

Current Oncology Reports, 2009
Peter P Sayeski, Sayeski Peter P
exaly  

Splenomegaly and the JAK2 V617F mutation

European Journal of Internal Medicine, 2017
openaire   +2 more sources

A Novel Selective JAK2 Inhibitor Identified Using Pharmacological Interactions

Frontiers in Pharmacology, 2018
Tony Eight Lin, WEI-CHUN Huangfu, Min-Wu Chao   +2 more
exaly  

Should myeloid and lymphoid neoplasms with PCM1‐JAK2 and other rearrangements of JAK2 be recognized as specific entities?

British Journal of Haematology, 2014
Barbara J Bain
exaly  

Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms

Blood Cancer Journal, 2011
Kotaro Shide, Kazuya Shimoda, Shimoda K   +2 more
exaly  

Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation

Proceedings of the National Academy of Sciences of the United States of America, 2018
Brian C Betts, David Bastian, Supinya Iamsawat   +2 more
exaly  

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

Lancet, The, 2005
Linda M Scott, George S Vassiliou, Anthony J Bench   +2 more
exaly